FDA PMA decision (AdCom / approval / CRL / label / post-market)
גבוה חברת אבחון שמפתחת בדיקת דם (Galleri) לגילוי מוקדם של סוגי סרטן רבים, לפני אבחנה.
השקעה ביצירת קטגוריה של גילוי סרטן מוקדם — תלויה באישור FDA, בכיסוי ביטוחי ובאימוץ איכותי.
- מצב התזה
- שלמה ומבוססת-עדות יותר מבעבר, אך לא מנוטרלת-סיכון במלואה.
- תפקיד בתיק
- פוזיציית אופציה: פוטנציאל גבוה / אי-ודאות גבוהה ביצירת קטגוריית MCED.
- מסגרת פעולה
- החזקה / מעקב (Hold / Monitor)
- טריגר לסקירה
- עדכון FDA, עדכון CMS/משלמים, דוח רבעוני, פרסום קליני או עדכון מתחרה מהותי.
- גישת הערכה
- Scenario-based; no single price target
מצריך סקירה אנושית שווי / משקל: לא מחושב
מה חייב לקרות
- FDA approval of the Galleri PMA
- CMS / Medicare coverage materializes on workable criteria and timing
- Commercial payers adopt coverage
- Volume is high-quality, reimbursed and repeatable, not mainly self-pay
- Durable net ASP and gross-margin scale
- Cash burn declines meaningfully
- GRAIL keeps a leading position versus Guardant and Exact/Abbott
מה יכול לשבור את התזה
- FDA rejection or a severe regulatory setback
- CMS pathway closes or becomes restrictive/delayed beyond reason
- Peer-reviewed PATHFINDER 2 / NHS-Galleri materially weaker than company framing
- Volume stays mostly low-quality self-pay; repeat testing stays weak
- ASP collapses
- Burn stays high and financing becomes distressed
- Guardant or Exact/Abbott overtakes GRAIL materially
- Management credibility deteriorates
הקטליסטים הבאים
CMS publishes implementation guidance or begins a coverage process
גבוה Commercial payers publish Galleri coverage policies
גבוה Quarterly Galleri volume, revenue and implied ASP trend
גבוה Peer-reviewed PATHFINDER 2 publication
גבוה Peer-reviewed NHS-Galleri publication
גבוה הסיכונים המרכזיים
FDA approval delayed, denied, narrowed, or burdened
Reimbursement fails to expand beyond limited/self-pay channels
Mortality benefit unproven; payer skepticism after NHS-Galleri primary endpoint miss
Volume growth without high-quality reimbursed adoption (self-pay/discounted)
ASP compression from channel mix and consumer pricing
High cash burn may require further dilutive financing
Competition from Guardant Shield MCD and Exact/Abbott Cancerguard
KPI למעקב
- Q1 2026 Galleri revenue
- $39.8M — +37% YoY
- Q1 2026 test volume
- >56,000 — +50% YoY; volume outpaced revenue (ASP pressure)
- Implied revenue per test
- ~$711 — directional; vs $949 list price
- Cash + short-term securities (Q1 end)
- $823.1M — plus $110M Samsung financing post-Q1
- Q1 2026 adjusted EBITDA
- $(79.9)M — burn remains high
- Q1 2026 net loss
- $(93.2)M — improved YoY
- Q1 2026 operating cash use
- $(87.0)M — runway depends on burn reduction
- Shares outstanding (Q1 end)
- 41.134M — $189.3M ATM capacity remaining
כללי פעולה — מסגרת, לא המלצה
הוספה (Add)
- Thesis materially strengthens
- FDA / CMS / reimbursement probability improves
- Price implies mostly bear-case assumptions
- High-quality volume improves and implied ASP stabilizes
- Burn declines meaningfully
- Peer-reviewed clinical evidence strengthens the thesis
- Position size remains within risk limits
- Do not add only because price fell or thesis is weakening
החזקה (Hold)
- Thesis intact; valuation not obviously excessive
- Catalyst path remains alive; evidence mixed but not broken
- Risk/reward acceptable; position size appropriate
קיצוץ (Trim)
- Valuation prices in bull/blue-sky before evidence
- Stock rises faster than evidence; position too concentrated
- Trim is risk management, not thesis rejection
יציאה (Exit)
- FDA / CMS / payer path breaks
- Clinical evidence materially weakens; volume quality fails; ASP collapses
- Dilution becomes severe; management loses credibility
- Competitor displacement becomes likely
שאלות פתוחות
FDA approval outcome
קריטי CMS coverage criteria and timing
קריטי Commercial payer adoption
קריטי Peer-reviewed PATHFINDER 2 and NHS-Galleri publications
גבוה Mortality benefit or strong health-economic evidence
גבוה Payer mix and reimbursed share of volume
גבוה Repeat-testing behavior
גבוה Channel-level ASP and gross margin
גבוה Long-term dilution risk
בינוני מקורות בריפו
נתיבים בריפו (מקור האמת) — לעיון, לא קישורים פעילים:
ai-context/company-briefs/gral-he.md companies/gral/dashboard.mdcompanies/gral/thesis.mdcompanies/gral/ic-memo.mdcompanies/gral/risks.mdcompanies/gral/catalysts.mdcompanies/gral/monitoring/README.mdcompanies/gral/working-notes.md
Derived from companies/gral/ — the repo is the source of truth. No price targets, no buy/sell recommendation. NHS-Galleri did not meet its primary endpoint; the Stage IV reduction was a secondary endpoint. Litigation is allegations only. FDA review is not approval; approval would not guarantee reimbursement.